KALA BIO, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
KALA Nasdaq 2836 www.kalarx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for KALA BIO, Inc.

KALA BIO Announces Reverse Stock Split - May 7th, 2026 7:00 am
Aterian, Inc. Announces Definitive Agreement for the Sale of its Marquee Brand Portfolio for $18 Million Subject to Adjustments - Apr 28th, 2026 6:00 am
Kala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic Medicine - Apr 21st, 2026 5:00 am
Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities - Apr 1st, 2026 4:45 am
KALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now Live - Mar 30th, 2026 6:45 am
Red Light Holland Engages Kala Bio’s Researgency.AI Platform to Support Clinical Development of Filament’s Patented PEX010 Botanical Psilocybin Drug Candidate - Mar 18th, 2026 7:00 am
Red Light Holland Engages Kala Bio's Researgency.ai Platform to Support Clinical Development of Filament Health's Patented PEX010 Botanical Psilocybin Drug Candidate - Mar 18th, 2026 6:15 am
Younet.ai Highlights Researgency.ai Collaboration with Kala Bio (KALA) as New "AutoResearch" Milestone Signals the Rise of Autonomous Research Agents - Mar 11th, 2026 9:18 am
BC-Most Active Stocks - Mar 11th, 2026 8:30 am
Kala Bio Launches a Revolution for Biotech- First AI Agent Deploying in 14 Days as $180 Billion Agentic AI Healthcare Revolution Accelerates - Mar 11th, 2026 4:30 am
Stock Trend Capital Provides Younet AI Investment Update - Mar 9th, 2026 4:20 am
KALA BIO Announces Strategic Initiative to Deploy and Continue to Develop an On-Premises AI Infrastructure Platform for the Biotech Industry; Enters Into Platform Development and Exclusive License Agreement for Proprietary AI Research Platform “Researgency” - Mar 4th, 2026 4:30 am
KALA BIO Settles Approximately $10.6 million of Debt - Jan 5th, 2026 2:10 pm
KALA BIO Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules - Dec 5th, 2025 12:36 pm
KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules - Dec 4th, 2025 8:45 am
Top Midday Gainers - Dec 1st, 2025 11:32 am
KALA BIO Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar - Dec 1st, 2025 5:00 am
KALA BIO: Q3 Earnings Snapshot - Nov 19th, 2025 4:11 pm
KALA Stock Crashes 88% in a Month Following Eye Disorder Study Failure - Oct 8th, 2025 9:18 am
Top Midday Decliners - Sep 30th, 2025 12:22 pm